Navigation path

VIAV


HIV/AIDS

Very Innovative AIDS Vaccine
Framework programme:
6
Call:
2
Project number:
LSHP-CT-2004-012188
EC contribution:
€ 1,000,000
Duration:
24 months
Type:
STREP
Starting date:
1 January 2005

Keywords: Infections; vaccines; immunology; AIDS; HIV; Tat protein; Env; Tat-Env complex; HIV entry; HIV neutralising antibodies

Summary:

The goal of the VIAV programme is to develop a novel, broadly effective HIV/AIDS vaccine based on HIV Tat and Env protein complexes. VIAV is built upon an international consortium of European experts in the fields of HIV/AIDS protein structure and molecular modelling/docking, biochemistry, molecular biology, virology, immunology, vaccine development, GMP production, trial conduction and field studies.

Background:

Results obtained by the VIAV Consortium indicate that the HIV Tat protein increases HIV cell adsorption, infectivity and tropisms by interacting with components of the HIV membrane and envelope protein (Env). Because the interaction between Tat and Env may allow the generation of complex-specific, neutralisation-sensitive epitopes and/or the stabilisation of cryptic and/or transiently exposed Env epitopes, a vaccine based on Tat-Env complexes is likely to generate protective immune responses against vulnerable viral targets.

Aim:

The aim of VIAV is to develop a highly innovative Tat-Env complex-based vaccine capable of inducing cross-clade neutralising antibodies against novel, neutralisation-sensitive Env epitopes to prevent HIV infection and/or AIDS progression. The VIAV aim will be achieved through new antigen design stemming out from novel virological, immunological and modeling data of the VIAV Consortium.

[+] Read More